Rigel Pharmaceuticals (RIGL)


Stock Price Forecast

March 26, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Rigel Pharmaceuticals chart...

About the Company

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

CEO

Raul Rodriguez

Exchange

NASDAQ

Website

https://www.rigel.com/

$85M

Total Revenue

280

Employees

$248M

Market Capitalization

-9.21

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RIGL News

RIGL Apr 2024 3.000 call

12d ago, source: Yahoo Finance

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over ...

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

14d ago, source:

KELOWNA, BC / ACCESSWIRE / March 14, 2024 / (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in ...

Chutes & Ladders—Voyager plucks another Biogen exec for top post

13d ago, source: FierceBiotech

Voyager Therapeutics plucks another Biogen exec, naming Ferguson as new CMO. Pfizer names CSO for anti-infectives research ...

Lexaria Bioscience (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

13d ago, source:

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Rigel Pharmaceuticals (RIGL) Is Worth Looking Despite A Loss Of -24.84% From High

20d ago, source:

Rigel Pharmaceuticals (NASDAQ:RIGL) on Friday, March 08, rose 2.61% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.57. A look at the stock’s price ...

News - Poseida Therapeutics

2d ago, source: The Pharma Letter

Shares of San Diego, USA-based biotech Poseida Therapeutics were up almost 98% at $4.80 late morning, after it announced it has entered into a broad strategic collaboration and license agreement with ...

Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth

6d ago, source:

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Armata Pharmaceuticals (ARMP – Research ...

Sangamo Biosciences Earns Buy Rating on Breakthrough Brain-Targeting Gene Therapy Capsid and Strategic Advancements

14d ago, source:

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating yesterday. Ritu Baral has given his Buy ...

Lexaria Bioscience Corp.: Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

14d ago, source:

KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment o ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...